READING, England, May 8 /PRNewswire/ --
- Meets Primary Efficacy Endpoint
- First Study of a Next-Generation Fentanyl-Based Product to Show Superiority Over Immediate Release Morphine
Archimedes Pharma Limited, the UK-based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for NasalFent(R), the Company's innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release morphine sulphate, the most commonly prescribed medicine for breakthrough cancer pain.